Streetbeat News

Stock Prices

GKOS

Glaukos Corporation (NYSE:GKOS) has announced agreements to exchange $230 million in principal amount of its 2.75% Convertible Senior Notes due 2027 for common stock. The transactions are expected to close around June 25, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:25 am

RZLT

Rezolute shares are trading lower following the company's announcement of a proposed public offering of common stock and pre-funded warrants.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:25 am

ADBE

Adobe shares are trading higher following better-than-expected Q2 earnings and strong guidance.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:25 am

VXRT

Vaxart shares are trading higher after the company received a BARDA-funded Project NextGen award valued up to $453 million to conduct a Phase 2b study evaluating its COVID-19 oral pill vaccine candidate.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:24 am

MSM

MSC Industrial Direct shares are trading lower after the company reported preliminary Q3 financial results below estimates and cut its FY24 adjusted operating margin.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:24 am

RH

RH shares are trading lower after the company reported mixed Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:24 am

KYMR

Kymera Therapeutics has shared new clinical data from its ongoing KT-333 Phase 1 trial. The data were presented at the European Hematology Association (EHA) Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:21 am

ACRS

CATX

ZOM

Insiders are aggressively buying shares of Aclaris Therapeutics, Zomedica, and Perspective Therapeutics. This insider activity could indicate confidence in these companies' prospects. Aclaris posted upbeat quarterly results, Zomedica launched a new software update, and Perspective Therapeutics announced a reverse stock split.

Portfolio Pulse from Avi Kapoor

June 14, 2024 | 11:15 am

BPTH

Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for treating acute myeloid leukemia at the 2024 European Hematology Association Congress. The data showed that prexigebersen is well-tolerated and has demonstrated compelling efficacy in both newly diagnosed and refractory/relapsed AML patients.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:11 am

IIPR

Innovative Industrial Properties, Inc. (NYSE:IIPR) announced a 4.4% increase in its second quarter 2024 dividend to $1.90 per share, payable on July 15, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:10 am